Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six ...
Al Bawaba

Introducing Galaxy Z TriFold: The Shape of What's Next in Mobile Innovation

Samsung Electronics Co., Ltd. announced the launch of Galaxy Z TriFold, further expanding Samsung’s leadership in new form ...
The Oakland Press on MSN

Oakland County community calendar Dec. 7 and beyond

• Oakland County Parks and Recreation offers free admission. General park entry fees and vehicle permits have been eliminated ...
Le Lézard

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...